Drug Profile

Research programme : cancer therapeutics - Wuxi MTLH Biotechnology

Alternative Names: MTLH-001-Wuxi; MTLH-002; MTLH-003; MTLH-004; MTLH001

Latest Information Update: 28 Feb 2020

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Wuxi MTLH Biotechnology
Class Antineoplastics; Peptides; Proteins
Mechanism of Action ERBB 2 receptor antagonists; Platelet-derived growth factor receptor antagonists; Transforming growth factor beta modulators; Tumour necrosis factor receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 Feb 2020 No recent reports of development identified for research development in Cancer in China
25 Jan 2016 Early research in Cancer in China (unspecified route)
25 Jan 2016 Wuxi MTLH Biotechnology has patent-protection in USA

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com